Contribute Try STAT+ Today

Good day, everyone! Nick Florko here filling in for the great Ed Silverman. I’m here in the beautiful Pine Tree State but today’s stimulation is, well, underwhelming. We are sipping a can of coffee because the other option was the motel’s continental breakfast. Here’s hoping your choices are better. Now for today’s news. …

A federal judge is pushing back his expected ruling on Purdue Pharma’s bankruptcy reorganization plan, Reuters reports. The judge, Robert Drain, was originally expected to rule on the plan by Friday but now anticipates making a ruling next Wednesday. The plan has garnered outsized attention in recent days because it would shield members of the wealthy Sackler family that own Purdue from future lawsuits regarding their role in the opioid crisis, in addition to massively restructuring the company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment